FrançaisArrowhead Pharmaceuticals (ARWR): financial analysis & fundamentals
📈 See the interactive version (live chart) →
Valuation & profitability
| Metric | Value | What it means |
|---|---|---|
| P/E (price / earnings) | — | The higher, the more growth the market expects. |
| Forward P/E | -18.2 | On next year's expected earnings. Lower than current P/E = rising earnings. |
| PEG (P/E ÷ growth) | — | Below 1 = cheap given growth; above 2 = expensive. |
| Net margin | -48% | Share of revenue that ends up as profit. |
| Revenue growth | 171% | Pace of revenue growth. |
| Price-to-book | 26.9 | Price relative to book value. |
| Market cap | $12.5 B | Total market value of the company. |
| Dividend yield | — | No dividend currently. |
Income statement (by year)
| Year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2022 | $243 M | $-176 M | -72% |
| 2023 | $241 M | $-205 M | -85% |
| 2024 | $4 M | $-599 M | -16882% |
| 2025 | $829 M | $-2 M | -0% |
📊 Open the interactive Arrowhead Pharmaceuticals page (charts, live news) →
Frequently asked questions
Is Arrowhead Pharmaceuticals stock expensive?
Arrowhead Pharmaceuticals has a P/E of — (forward P/E -18.2) and a PEG of —. A PEG below 1 is rather cheap given growth, above 2 is expensive. Verdict: valuation to review.
What is Arrowhead Pharmaceuticals's net margin?
Arrowhead Pharmaceuticals's net margin is about -48% — the share of revenue that ends up as net profit.
What is Arrowhead Pharmaceuticals's revenue?
Latest known revenue: $829 M for net income of $-2 M. The year-by-year breakdown is in the income statement above.
What is Arrowhead Pharmaceuticals's market cap?
Arrowhead Pharmaceuticals (ARWR) has a market cap of about $12.5 B.
Does Arrowhead Pharmaceuticals pay a dividend?
No, Arrowhead Pharmaceuticals does not currently pay a dividend (it reinvests earnings).
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Data: Yahoo Finance, recomputed by JPI Invest. A stock can be « cheap » for a bad reason.